SuperworthPERRIGO EPS PRGO
Diluted earnings per share by quarter and over the last twelve months, from 2012.
- Last 12 months, to Jun 27, 2026
- −$12.46
- Latest quarter, Q2 FY26
- $0.53
- Fiscal year 2025
- −$10.23
PERRIGO's earnings per share was −$12.46 over the twelve months to Jun 27, 2026.
In its latest quarter, Q2 FY26, it was $0.53.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$10.23 | n/a |
| FY2024 | −$1.25 | n/a |
| FY2023 | −$0.10 | n/a |
| FY2022 | −$1.05 | n/a |
| FY2021 | −$0.52 | n/a |
| FY2020 | −$1.20 | −212% |
| FY2019 | $1.07 | +14% |
| FY2018 | $0.94 | +12% |
| FY2017 | $0.84 | n/a |
| FY2016 | −$28.01 | −2873% |
| FY2015 | $1.01 | n/a |
| FY2015 | −$0.04 | −102% |
| FY2014 | $1.65 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $0.53 | n/a | −$12.46 | |
| Q1 FY26 | −$2.87 | n/a | −$13.05 | |
| Q4 FY25 | −$10.17 | n/a | −$10.23 | |
| Q3 FY25 | $0.05 | n/a | −$0.38 | |
| Q2 FY25 | −$0.06 | n/a | −$0.58 | |
| Q1 FY25 | −$0.05 | −600% | −$1.31 | |
| Q4 FY24 | −$0.32 | n/a | −$1.25 | |
| Q3 FY24 | −$0.15 | −250% | −$1.17 | |
| Q2 FY24 | −$0.79 | −1417% | −$0.92 | |
| Q1 FY24 | $0.01 | n/a | −$0.07 | |
| Q4 FY23 | −$0.24 | n/a | −$0.10 | |
| Q3 FY23 | $0.10 | n/a | −$0.04 |
Against its peers
Companies in Drug Manufacturers - General nearest PERRIGO's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| PRGOPERRIGO | −$12.46 | |
| PBHPrestige Consumer Healthcare | $3.57 | −16% a year |
| HRMYHarmony Biosciences | $3.09 | −0% a year |
| NRIXNurix Therapeutics | $2.31 | |
| ANIPANI Pharmaceuticals | $4.70 | |
| PAHCPhibro Animal Health | $2.44 | +107% a year |
| ANABAnaptysbio | $4.57 | |
| PCRXPacira BioSciences | $0.35 | |
| OGNOrganon | $0.77 | −71% a year |
| LQDALiquidia | $1.39 | |
| ARQTArcutis Biotherapeutics | $0.22 | |
| Peer median | $2.38 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on PERRIGO
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.